Table 1.

Gender	71% male
Median Age	61 (46–70)
Multiple Myeloma	34 patients
Median prior regimens	1 (range1–3)
Median cycles of prior chemotherapy	5 (range 1–12)
Prior lenalidomide (MM pts)	22 patients
Median prior cycles	4
1–4 cycles	13 patients
5–6 cycles	9 patients
Prior radiotherapy	3 patients
ISS Stage I (MM)	12 (40%)
ISS Stage II (MM)	10 (33%)
ISS Stage III (MM)	8 (27%)
High Risk Cytogenetics (MM)	9 patients
Median Monoclonal Protein (n=32)	0.3 g/dL (range 0–1.6)
Median Bone Marrow % Involvement by Morphology (MM)	3% (range 0–35%)